The prevalence of onchocerciasis in Africa and Yemen, 2000-2018: a geospatial analysis.
Geospatial model
Neglected tropical diseases
Onchocerciasis
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
07 09 2022
07 09 2022
Historique:
received:
15
03
2022
accepted:
14
07
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission. A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000-2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates of all-age 2000-2018 onchocerciasis infection prevalence at the 5 × 5-km resolution as well as aggregations to the national level, along with corresponding estimates of the uncertainty in these predictions. As of 2018, the prevalence of onchocerciasis infection continues to be concentrated across central and western Africa, with the highest mean estimates at the national level in Ghana (12.2%, 95% uncertainty interval [UI] 5.0-22.7). Mean estimates exceed 5% infection prevalence at the national level for Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Guinea-Bissau, Sierra Leone, and South Sudan. Our analysis suggests that onchocerciasis infection has declined over the last two decades throughout western and central Africa. Focal areas of Angola, Cameroon, the Democratic Republic of the Congo, Ethiopia, Ghana, Guinea, Mali, Nigeria, South Sudan, and Uganda continue to have mean microfiladermia prevalence estimates exceeding 25%. At and above this level, the continuation or initiation of mass drug administration with ivermectin is supported. If national programs aim to eliminate onchocerciasis infection, additional surveillance or supervision of areas of predicted high prevalence would be warranted to ensure sufficiently high coverage of program interventions.
Sections du résumé
BACKGROUND
Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission.
METHODS
A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000-2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates of all-age 2000-2018 onchocerciasis infection prevalence at the 5 × 5-km resolution as well as aggregations to the national level, along with corresponding estimates of the uncertainty in these predictions.
RESULTS
As of 2018, the prevalence of onchocerciasis infection continues to be concentrated across central and western Africa, with the highest mean estimates at the national level in Ghana (12.2%, 95% uncertainty interval [UI] 5.0-22.7). Mean estimates exceed 5% infection prevalence at the national level for Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Guinea-Bissau, Sierra Leone, and South Sudan.
CONCLUSIONS
Our analysis suggests that onchocerciasis infection has declined over the last two decades throughout western and central Africa. Focal areas of Angola, Cameroon, the Democratic Republic of the Congo, Ethiopia, Ghana, Guinea, Mali, Nigeria, South Sudan, and Uganda continue to have mean microfiladermia prevalence estimates exceeding 25%. At and above this level, the continuation or initiation of mass drug administration with ivermectin is supported. If national programs aim to eliminate onchocerciasis infection, additional surveillance or supervision of areas of predicted high prevalence would be warranted to ensure sufficiently high coverage of program interventions.
Identifiants
pubmed: 36068517
doi: 10.1186/s12916-022-02486-y
pii: 10.1186/s12916-022-02486-y
pmc: PMC9449300
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
293Investigateurs
Chris A Schmidt
(CA)
Elizabeth A Cromwell
(EA)
Elex Hill
(E)
David M Pigott
(DM)
Jaffar Abbas
(J)
Victor Adekanmbi
(V)
Olatunji O Adetokunboh
(OO)
Muktar Beshir Ahmed
(MB)
Fahad Mashhour Alanezi
(FM)
Turki M Alanzi
(TM)
Vahid Alipour
(V)
Catalina Liliana Andrei
(CL)
Tudorel Andrei
(T)
Davood Anvari
(D)
Seth Christopher Yaw Appiah
(SCY)
Muhammad Aqeel
(M)
Jalal Arabloo
(J)
Mohammad Asghari Jafarabadi
(MA)
Marcel Ausloos
(M)
Atif Amin Baig
(AA)
Maciej Banach
(M)
Till Winfried Bärnighausen
(TW)
Krittika Bhattacharyya
(K)
Zulfiqar A Bhutta
(ZA)
Ali Bijani
(A)
Oliver J Brady
(OJ)
Nicola Luigi Bragazzi
(NL)
Zahid A Butt
(ZA)
Felix Carvalho
(F)
Vijay Kumar Chattu
(VK)
Saad M A Dahlawi
(SMA)
Giovanni Damiani
(G)
Feleke Mekonnen Demeke
(FM)
Kebede Deribe
(K)
Samath Dhamminda Dharmaratne
(SD)
Daniel Diaz
(D)
Alireza Didarloo
(A)
Lucas Earl
(L)
Maysaa El Sayed Zaki
(MES)
Maha El Tantawi
(M)
Nazir Fattahi
(N)
Eduarda Fernandes
(E)
Nataliya A Foigt
(NA)
Masoud Foroutan
(M)
Richard Charles Franklin
(RC)
Yuming Guo
(Y)
Arvin Haj-Mirzaian
(A)
Samer Hamidi
(S)
Hadi Hassankhani
(H)
Claudiu Herteliu
(C)
Tarig B Higazi
(TB)
Mostafa Hosseini
(M)
Mehdi Hosseinzadeh
(M)
Mowafa Househ
(M)
Olayinka Stephen Ilesanmi
(OS)
Irena M Ilic
(IM)
Milena D Ilic
(MD)
Seyed Sina Naghibi Irvani
(SSN)
Ravi Prakash Jha
(RP)
John S Ji
(JS)
Jost B Jonas
(JB)
Jacek Jerzy Jozwiak
(JJ)
Leila R Kalankesh
(LR)
Naser Kamyari
(N)
Behzad Karami Matin
(BK)
Salah Eddin Karimi
(SE)
Gbenga A Kayode
(GA)
Ali Kazemi Karyani
(AK)
Ejaz Ahmad Khan
(EA)
Md Nuruzzaman Khan
(MN)
Khaled Khatab
(K)
Mona M Khater
(MM)
Neda Kianipour
(N)
Yun Jin Kim
(YJ)
Soewarta Kosen
(S)
Dian Kusuma
(D)
Carlo La Vecchia
(C)
Van Charles Lansingh
(VC)
Paul H Lee
(PH)
Shanshan Li
(S)
Shokofeh Maleki
(S)
Mohammad Ali Mansournia
(MA)
Francisco Rogerlândio Martins-Melo
(FR)
Colm McAlinden
(C)
Walter Mendoza
(W)
Tomislav Mestrovic
(T)
Masoud Moghadaszadeh
(M)
Abdollah Mohammadian-Hafshejani
(A)
Seyyede Momeneh Mohammadi
(SM)
Shafiu Mohammed
(S)
Rahmatollah Moradzadeh
(R)
Paula Moraga
(P)
Mehdi Naderi
(M)
Ahamarshan Jayaraman Nagarajan
(AJ)
Ionut Negoi
(I)
Cuong Tat Nguyen
(CT)
Huong Lan Thi Nguyen
(HLT)
Bogdan Oancea
(B)
Andrew T Olagunju
(AT)
Ahmed Omar Bali
(AO)
Obinna E Onwujekwe
(OE)
Adrian Pana
(A)
Vafa Rahimi-Movaghar
(V)
Kiana Ramezanzadeh
(K)
David Laith Rawaf
(DL)
Salman Rawaf
(S)
Reza Rawassizadeh
(R)
Aziz Rezapour
(A)
Ana Isabel Ribeiro
(AI)
Abdallah M Samy
(AM)
Masood Ali Shaikh
(MA)
Kiomars Sharafi
(K)
Aziz Sheikh
(A)
Jasvinder A Singh
(JA)
Eirini Skiadaresi
(E)
Shahin Soltani
(S)
Wilma A Stolk
(WA)
Mu'awiyyah Babale Sufiyan
(MB)
Alan J Thomson
(AJ)
Bach Xuan Tran
(BX)
Khanh Bao Tran
(KB)
Bhaskaran Unnikrishnan
(B)
Francesco S Violante
(FS)
Giang Thu Vu
(GT)
Tomohide Yamada
(T)
Sanni Yaya
(S)
Paul Yip
(P)
Naohiro Yonemoto
(N)
Chuanhua Yu
(C)
Yong Yu
(Y)
Maryam Zamanian
(M)
Yunquan Zhang
(Y)
Zhi-Jiang Zhang
(ZJ)
Arash Ziapour
(A)
Simon I Hay
(SI)
Informations de copyright
© 2022. The Author(s).
Références
Clin Infect Dis. 2020 May 23;70(11):2281-2289
pubmed: 31304961
Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S29-39
pubmed: 12081248
Nature. 2018 Feb 28;555(7694):41-47
pubmed: 29493591
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Acta Trop. 2013 Jun;126(3):218-21
pubmed: 23458325
Parasit Vectors. 2014 Jul 22;7:326
pubmed: 25053392
Am J Trop Med Hyg. 2016 Nov 2;95(5):1037-1040
pubmed: 27352878
Am J Trop Med Hyg. 2012 Aug;87(2):216-22
pubmed: 22855750
N Engl J Med. 2017 Nov 23;377(21):2044-2052
pubmed: 29116890
PLoS One. 2014 Dec 29;9(12):e115886
pubmed: 25545677
Wkly Epidemiol Rec. ;92(45):681-94
pubmed: 29130679
Int Health. 2018 Mar 1;10(suppl_1):i20-i26
pubmed: 29471336
Clin Infect Dis. 2018 Jun 1;66(suppl_4):S267-S274
pubmed: 29860291
Ann Trop Med Parasitol. 1976 Sep;70(3):343-54
pubmed: 971003
PLoS Negl Trop Dis. 2021 Jul 28;15(7):e0008824
pubmed: 34319976
PLoS Negl Trop Dis. 2015 May 14;9(5):e0003507
pubmed: 25974081
PLoS Negl Trop Dis. 2009;3(3):e404
pubmed: 19333366
Lancet. 2017 Nov 11;390(10108):2171-2182
pubmed: 28958464
Int Health. 2018 Mar 1;10(suppl_1):i79-i88
pubmed: 29471335
PLoS Negl Trop Dis. 2016 Jan 15;10(1):e0004328
pubmed: 26771545
Nature. 2019 Oct;574(7778):353-358
pubmed: 31619795
Am J Trop Med Hyg. 2013 Jul;89(1):51-7
pubmed: 23690554
Int Health. 2018 Mar 1;10(suppl_1):i1-i2
pubmed: 29471347
Int Health. 2018 Mar 1;10(suppl_1):i71-i78
pubmed: 29471334
PLoS Negl Trop Dis. 2013 Apr 11;7(4):e2168
pubmed: 23593528
Lancet Glob Health. 2020 Sep;8(9):e1186-e1194
pubmed: 32827480